Cramarossa Gemma, Lee Esther K, Sivanathan Lavarnan, Georgsdottir Soley, Lien Kelly, Santos Keemo Delos, Chan Kelvin, Emmenegger Urban
Division of Medical Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada.
Biomark Med. 2014;8(6):893-911. doi: 10.2217/bmm.14.14.
Low-dose metronomic (LDM) chemotherapy is a beneficial and very well-tolerated form of chemotherapy utilization characterized by the frequent and uninterrupted administration of low doses of conventional chemotherapeutic agents over prolonged periods of time. While patients resistant to standard maximum tolerated dose (MTD) chemotherapy may still benefit from LDM chemotherapy, there is a lack of predictive markers of response to LDM chemotherapy. We searched the MEDLINE, EMBASE, CENTRAL and PubMed databases for correlative studies conducted as part of LDM chemotherapy trials in order to identify the most promising biomarker candidates. Given the antiangiogenic properties of LDM chemotherapy, angiogenesis-related biomarkers were most commonly studied. However, significant correlations between angiogenesis-related biomarkers and study end points were rare and variable, even so far as biomarkers correlating positively with an end point in some studies and negatively with the same end point in other studies. Pursuing biomarkers outside the angiogenesis field may be more promising.
低剂量节拍式（LDM）化疗是一种有益且耐受性良好的化疗应用形式，其特点是在较长时间内频繁且不间断地给予低剂量的传统化疗药物。虽然对标准最大耐受剂量（MTD）化疗耐药的患者仍可能从LDM化疗中获益，但缺乏LDM化疗反应的预测标志物。我们检索了MEDLINE、EMBASE、CENTRAL和PubMed数据库，以查找作为LDM化疗试验一部分进行的相关性研究，以便确定最有前景的生物标志物候选物。鉴于LDM化疗的抗血管生成特性，与血管生成相关的生物标志物是最常研究的。然而，血管生成相关生物标志物与研究终点之间的显著相关性很少且不一致，甚至在某些研究中与终点呈正相关的生物标志物在其他研究中与相同终点呈负相关。在血管生成领域之外寻找生物标志物可能更有前景。
